Parkinson's disease subtypes: Clinical classification and ventricular cerebrospinal fluid analysis

Parkinsonism and Related Disorders

Volumn 6, Issue 2, 2000, Pages 69-76

  Schiess, M C ^a   Zheng, H ^a   Soukup, V M ^b   Bonnen, J G ^b   Nauta, H J W ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

High pressure liquid chromatography; Parkinson's disease subtypes; PD classification; Ventricular cerebrospinal fluid

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; GLYCINE; NEUROTRANSMITTER;

ADULT; AGED; AMINO ACID ANALYSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0034005254     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00051-6     Document Type: Article

References (36)

1. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
2. Mjones H. Paralysis agitans: a clinical and genetic study. Acta Psychiatry Neurol Scand (Suppl). 54:1949;1-195.
3. Birkmayer W., Riederer P., Youdim B.H. Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg. 81:1979;158-164.
4. Rinne U.K., Sonninen V., Siirtola T., Marttila R. Long-term responses of Parkinson's disease to levodopa therapy. J Neural Transm Suppl. 16:1980;149-156.
5. Barbeau A., Porcher E. New data on the genetics of Parkinson's disease. Can J Neurol Sci. 9:1982;53-60.
6. Hershey L.A., Feldman B.J., Kim K.Y., Commichau C., Lichter D.G. Tremor at onset. Predictor of cognitive and motor outcome in Parkinson's disease? Arch Neurol. 48:1991;1049-1051.
7. Lieberman A., Dziatolowski M., Kupersmith M., Serby M., Goodgold A., Korein J., Goldstein M. Dementia in Parkinson's disease. Ann Neurol. 6:1979;355-359.
8. Marttila R.J., Rinne U.K. Dementia in Parkinson's disease. Acta Neurol Scand. 54:1976;431-441.
9. Starkstein S.E., Mayberg H.S., Leiguarda R., Preziosi T.J., Robinson R.G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 55:1992;377-382.
10. Jankovic J., McDermott M., Carter J., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology. 40:1990;1529-1534.
11. Paulus W., Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 50:1991;743-755.
12. Rajput A.H., Pahwa R., Pahwa P., Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology. 43:1993;829-830.
13. Richards M., Marder K., Cote L., Mayeux R. Interrater reliability of the unified Parkinson's disease rating scale motor examination. Mov Disord. 9:1994;89-91.
14. Van Hilton J.J., van der Zwan A.D., Zwinderman A.H., Roos R.A. Rating impairment and disability in Parkinson's disease: evaluation of the unified Parkinson's disease rating scale. Mov Disord. 9:1994;84-88.
15. Fahn S., Elton R.L. Members of the UPDRS development committee: unified Parkinson's disease rating scale. Fahn S., Marsden C.D., Goldstein M., Calne D. Recent developments in Parkinson's disease. 1987;433 Macmillan, New York.
16. Martinez-Martin P., Gil-Nagel A., Gracia L.M., Gomez J.B., Martinez-Sarries J., Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. The cooperative multicentric group. Mov Disord. 9:1994;76-83.
17. Stebbins G.T., Goetz C.G. Factor structure of the unified Parkinson's disease rating scale: motor examination section. Mov Disord. 13:1998;633-636.
18. Liu D.X., Valadez V., Sorkin L.S., McAdoo D.J. Norepinephrine and serotonin release upon impact injury to rat spinal cord. J Neurotrauma. 7:1990;219-227.
19. Lunte S.M., Mohabbat T., Wong O.S., Kuwana T. Determination of desmosine, isodesmosine, and other amino acids by liquid chromatography with electrochemical detection following precolumn derivatization with napthalenedialdehyde/cyanide. Anal Biochem. 178:1989;202-207.
20. Koning H., Wolf H., Venema K., Korf J. Automated precolumn derivatization of amino acids, small peptides, brain amines and drugs with primary amino groups for reversed-phase high performance liquid chromatography using napthalenedialdehyde as the fluorogenic label. J Chromatogr. 533:1990;171-178.
21. Schiess M.C., Zheng H., Bonnen J.G., Nauta H.J.W., Soukup V.M. Correlation of ventricular CSF concentration of 5-hydroxyindole acetic acid (5-HIAA) and glycine to dominant symptomatology in Parkinson's disease [Abstract]. Mov Disord. 13:(Suppl 2):1998;180.
22. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin Neuropharmacol. 7:1984;35-49.
23. Clark W.G., Brater D.C., Johnson A.R. Goth's medical pharmacology. 13 :1992;Mosby, St. Louis.
24. Tabaddor K., Wolfson L.I., Sharpless N.S. Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology. 28:1978;1249-1253.
25. Papeschi R., Molina-Negro P., Sourkes T.L., Erba G. The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases. Neurology. 22:1972;1151-1159.
26. Fishman R.A. Composition of the cerebrospinal fluid. Cerebrospinal fluid in the diseases of the nervous system. 2 :1992;183-252.
27. Zetusky W.J., Jankovic J., Pirozzolo F.J. The heterogeneity of Parkinson's disease: clinical and prognostic implications. Neurology. 35:1985;522-526.
28. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med. 339:1998;1044-1053.
29. Lang A.E., Lozano A.M. Parkinson's disease. Second of two parts. N Engl J Med. 339:1998;1130-1143.
30. Rodriquez M.C., Obeso J.A., Olanow C.W. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target of neuroprotection. Ann Neurol. 44:(3 Suppl 1):1998;S175-S188.
31. Rinvik E., Ottersen O.P. Terminals of subthalamonigral fibers are enriched with glutamate-like immunoreactivity: an electron microscopic, immunogold analysis in the cat. J Chem Neuroanat. 6:1993;19-30.
32. Brotchie J., Crossman A., Mitchell I., et al. Chemical signalling in the globus pallidus in parkinsonism. Prog Brain Res. 99:1993;125-139.
33. Starkstein S.E., Petracca G., Chemerinski E., Teson A., Sabe L., Merello M., Leiguarda R. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord. 13:1998;29-33.
34. Johannsson B., Roos B.E. 5-Hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid of patients with neurological diseases. Eur Neurol. 11:1974;37-45.
35. Koskiniemi M., Laakso J., Kuurne T., Laipio M., Harkonen M. Indole levels in human lumbar and ventricular cerebrospinal fluid and the effect of L-tryptophan administration. Acta Neurol Scand. 71:1985;127-132.
36. Scheinin M. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity? Med Biol. 63:1985;1-17.